Physicians' attitudes and the use of oral anticoagulants: Surveying the present and envisioning future

Journal of Thrombosis and Thrombolysis

Volumn 16, Issue 1-2, 2003, Pages 33-37

  York, Meghan ^a   Agarwal, Ashish ^a   Ezekowitz, Michael ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; PLACEBO; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ADULT; AGE DISTRIBUTION; AGED; ANAMNESIS; ANTICOAGULATION; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ELDERLY CARE; EVIDENCE BASED MEDICINE; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MALE; MEDICAL EDUCATION; MEDICAL PRACTICE; PATIENT COMPLIANCE; PATIENT MONITORING; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; SURGICAL TECHNIQUE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VEIN CATHETERIZATION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; ATTITUDE OF HEALTH PERSONNEL; HUMANS; PHYSICIAN'S ROLE;

EID: 1842778900     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:THRO.0000014590.83591.4c     Document Type: Article

References (38)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991;22:983-988.
2. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476-484.
3. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995;155(5):469-473.
4. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The Anticoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375.
5. Frost L, Engholm G, Johnsen S, Moller H, Husted S. Incident stroke after discharge from the hospital with a diagnosis of atrial fibrillation. Am J Med 2000;108:36-40.
6. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457.
7. Kopecky SL. Management decisions in lone atrial fibrillation. Hosp Pract 1992;27:135-150.
8. Gajewski J, Singer RB. Mortality in an insured population with atrial fibrillation. JAMA 1981;245:1540-1544.
9. Laupacis A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest 1995;108(suppl4):352S-359S.
10. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323(29):1505-1511.
11. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK study. Lancet 1989;1:175-179.
12. Stroke Prevention in Atrial Fibrillation Investigators. Design of a multicenter randomized trial for the Stroke Prevention in Atrial Fibrillation study. Stroke 1990;21: 538-545.
13. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol 1991;18:349-355.
14. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation: The Veterans Affairs Cooperative Study. N Engl J Med 1992;327:1406-1412.
15. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low intensity, fixed dose, warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trials. Lancet 1996;348:633-638.
16. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med 1999;131:492-501.
17. Van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: An individual patient meta-analysis. JAMA 2002;288:2441-2448.
18. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 1993;342:1255-1262.
19. Hyleck EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest dose of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-546.
20. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 1993;342:1255-1262.
21. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: A meta-analysis of randomized controlled trials. JAMA 1998;280:1930-1935.
22. Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Internal Medicine 1994:154.
23. Stafford R, Singer D. National patterns of warfarin use in atrial fibrillation. Arch Internal Medicine 1996;156:2537-2541.
24. Bungard T, Ghali W, Teo K, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Internal Medicine 2000;160:41-46.
25. Hamby L, Weeks WB, Malikowski C. Complications of warfarin therapy: Causes, costs, and the role of the anticoagulation clinic. Effective Clinical Practice 2000;3:179-184.
26. Hixson-Wallace JA, Dotson JB, Blakey SA. Effect of regimen complexity on patient satisfaction and compliance with warfarin therapy. Clinical Applied Thrombosis/ Hemostasis 2001;7:33-37.
27. Lip GY, Kamath S, Jafri M, Mohammed A, Bareford D. Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: The West Birmingham Atrial Fibrillation Project. Stroke 2002;33:238-242.
28. Monette J, Gurwitz J, Rochon P, et al. Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: Results of a survey of long term care practitioners. J Am Geriatr Soc 1997;45:1060-1065.
29. Gross CP, Vogel EW, Dhondi AJ, et al. Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: A cross-sectional survey. Clinical Therapeutics 2003;25:1750-1764.
30. Chang H, Bell J, Devoo D, Kirk J, Wasson J. Physician variation in anticoagulating patients with atrial fibrillation. Arch Intern Med 1990;150:81-84.
31. Lee T, Pearson S, Johnson P, Garcia T, Weisberg M, Guadagnoli E. Failure of information as an intervention to modify clinical management. Ann Intern Med 1995;122:434-437.
32. Halperin JL. A long-term randomized trial comparing ximelagatran with warfarin for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 2003 March. www.acc03online.acc.org/ ondemand/trials3.
33. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996;61:755-759.
34. Johnson WD, Ganjoo AK, Stone CD, et al. The left atrial appendage: Our most lethal human attachment! Surgical implications. European Journal of Cardio-Thoracic Surgery 2000;17:718-722.
35. Odell JA, Blackshear JL, Davies E, et al. Thoracoscopic obliteration of the left atrial appendage: Potential for stroke reduction? Ann Thorac Surg 1996;61:565-567.
36. Sieverti H, Lesh M, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high risk patients with atrial fibrillation: Early clinical experience. Circulation 2002;105:1887-1889.
37. Nakai T, Lesh M, Gerstenfeld E, et al. Percutaneous left atrial appendage occlusion for preventing cardioembolism: First experience in canine model. Circulation 2002;105:2217-2222.
38. Harris D, Leor J, Assaf Y, et al. Convergence and stabilization of cellular proliferation into cellular steady state over the permanent arterial filtration struts of the Diverter: A novel percutaneous device for protection against embolic stroke. J Am Coll Cardiol 2003;41:300A-301A.